"The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked a"...
Retavase® (Reteplase) is a non-glycosylated deletion mutein of tissue plasminogen activator (tPA), containing the kringle 2 and the protease domains of human tPA. Retavase® (reteplase) contains 355 of the 527 amino acids of native tPA (amino acids 1-3 and 176-527). Retavase® (reteplase) is produced by recombinant DNA technology in E.coli. The protein is isolated as inactive inclusion bodies from E.coli, converted into its active form by an in vitro folding process and purified by chromatographic separation. The molecular weight of Reteplase is 39,571 daltons.
Potency is expressed in units (U) using a reference standard which is specific for Retavase® (reteplase) and is not comparable with units used for other thrombolytic agents.
Retavase® (reteplase) is a sterile, white, lyophilized powder for intravenous bolus injection after reconstitution with Sterile Water for Injection, USP (without preservatives). Following reconstitution, the pH is 6.0 ± 0.3. Retavase® (reteplase) is supplied as a 10.4 unit vial to ensure sufficient drug for administration of each 10 unit injection. Each single-use vial contains:
|Tranexamic Acid||8.32 mg|
|Dipotassium Hydrogen Phosphate||136.24 mg|
|Phosphoric Acid||51.27 mg|
Last reviewed on RxList: 9/15/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Retavase Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.